IMP

Dược phẩm Imexpharm ·HOSE ·2026Q1

▲ Slightly positive

Earnings conversion is confirmed CFO/NPAT 0.82x
Price
45,300
Latest close
03 Jun 2026
P/E 22.27x
P/B 2.93x
EPS 2,034
BVPS 15,441
ROE 15.4%
ROA 12.4%
Profit Margin 14.9%
Asset Turnover 0.83x
Equity Mult. 1.24x

TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity

What Is Changing

On a TTM 2026Q1 basis, IMP shows mild improvement in both revenue and margins, but the magnitude of change is narrow — profit is at an all-time high. This signal only becomes convincing if the improvement widens in coming periods.

TTM REVENUE
VND 2,393bn
+3.7%YoY
NET MARGIN
14.90%
+0.5ppYoY
TTM NET PROFIT
VND 357bn
+7.0%YoY
Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24 Q4'23 Q3'23 Q2'23
Revenue 546.2 640.8 573.6 632.7 594.1 652.1 544.7 517.2 491.1 608.2 466.9 439.7
Growth -15% +12% -9% +7% -9% +20% +5% +5% -19% +30% +6%
Net Income 82.0 107.5 76.9 90.3 74.5 120.6 72.4 65.9 61.9 72.3 69.7 79.7
Net Margin 15.02% 16.77% 13.41% 14.27% 12.53% 18.50% 13.29% 12.75% 12.61% 11.90% 14.93% 18.12%

Drivers of IMP's profit

TTM

Net profit attributable to parent increased vs last year, mainly helped by higher gross profit. Supporting and offsetting drivers:

Gross profit ↑ 84.3bn
Financial income ↑ 8.1bn
Selling expenses ↑ 27.9bn
Administrative expenses ↑ 22.7bn
Finance costs ↑ 9.7bn
Tax ↑ 8.7bn
TTM

Net profit attributable to parent increased vs prior quarter, mainly helped by lower selling expenses. Supporting and offsetting drivers:

Selling expenses ↓ 10.0bn
Finance costs ↓ 2.1bn
Administrative expenses ↓ 1.7bn
Financial income ↑ 1.1bn
Gross profit ↓ 7.8bn

Financial Highlights

Detailed analysis of each financial dimension

ROE = Profit Margin × Asset Turnover × Equity Multiplier

2025Q1 15.2% = 14.4% × 0.86 × 1.23
2026Q1 15.4% = 14.9% × 0.83 × 1.24

ROE is broadly flat at 15.4% — the components are offsetting one another.

Net margin: 14.9% +0.5pp Asset turnover: 0.83x -0.02x Leverage: 1.24x +0.01x

Is the profit sustainable?

Margins are improving and earnings quality is solid — a durable foundation for ROE.

very positive positive stable watch under pressure

What is driving the margin?

Net margin edged up to 14.90%, rising 0.5pp. Core operating signals are improving as Gross margin rose 2.1pp are enough to offset pressure from SG&A / Revenue rose 1.4pp (with lingering pressure from Net financial result / Revenue fell 0.1pp and Other profit / Revenue fell 0.0pp).

The improvement comes from core operations — this is a high-quality margin expansion.

Profitability trend

Net Margin 14.90% +0.5pp
Gross Margin 41.52% +2.1pp
SG&A / Revenue 22.04% +1.4pp

TTM YoY · 2025Q1 -> 2026Q1

Is capital being used efficiently?

Evaluate capital, asset, and working-capital efficiency.

Is capital being deployed efficiently?

ROIC stands at 14.69%, broadly flat versus the same period. That translates to 14.69 in after-tax operating profit for every 100 units of operating capital. NOPAT margin rose 0.5pp, but capital turnover broadly stable, while invested capital rose by 173bn — the two factors are offsetting each other, keeping overall ROIC nearly unchanged.

Overall ROIC is flat while internal components are moving — watch which side becomes dominant in coming periods.

CAPITAL EFFICIENCY TREND

TTM YoY · 2025Q1 -> 2026Q1

ROIC 14.69% −0.1pp
NOPAT Margin 14.85% +0.5pp
Capital Turnover 0.99x −0.04x
Average Invested Capital 2,418.1bn +173.2bn

Balance Sheet

Capital structure is conservative with low leverage — liabilities at 0.21x equity, net debt at 0.05x equity.

Inventory ended the period at 677.7bn, roughly 24.4% of total assets.

Over the last 12 months, working capital released 247.5bn of cash, mainly thanks to lower receivables and lower inventories. Pressure from lower payables only partly offset that benefit.

Working Capital Drivers

TTM YoY · 2025Q1 -> 2026Q1

Receivables decreased → higher CFO: +271.7bn
Inventories decreased → higher CFO: +20.2bn
Payables decreased → lower CFO: −44.4bn

Working Capital Efficiency

Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 5.9 days versus the same period last year. The main moves came from DIO fell 8.6 days, DSO rose 4.3 days, and DPO rose 1.6 days.

Improvement comes mainly from faster inventory turnover — watch whether this trend persists in coming periods.

Watchpoints

Cash conversion cycle remains stretched

CCC stands at 207.1 days, suggesting that working capital remains tied up for a relatively long operating cycle.

Receivables collection is slowing

DSO increased by +4.3 days, pointing to slower receivables turnover.

Working Capital Efficiency

TTM YoY · 2025Q1 -> 2026Q1

Receivables 59.0 days +4.3 days
Inventory 170.5 days −8.6 days
Payables 22.4 days +1.6 days
Cash Conversion Cycle 207.1 days −5.9 days

Is financial risk significant?

Financial risk is low — leverage is safe, both CFO and FCF are positive.

Leverage & Liquidity

Leverage looks fairly comfortable, with net debt / equity at 0.05x and interest coverage at 11.88x.

At present, short-term debt accounts for 50.0% of total debt, cash equals 37.9% of debt, and total debt stands at 200.0bn.

Leverage and liquidity trend

Net Debt / Equity 0.05x +0.01x
Interest Coverage 11.88x −2.95x
Cash / Debt 37.9% −40.0pp
Short-term Debt / Total Debt 50.0% +14.3pp
CFO / NI 0.82x +0.52x

TTM YoY · 2025Q1 -> 2026Q1

Cash Flow

With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 54.2bn in 2025, against investing cash flow of -76.6bn.

Post-investment cash flow was negative +22.4bn. Financing cash flow was positive +49.7bn.

CFO / net income was 0.82x.

After spending +14.7bn on fixed-asset investment, the business generated trailing free cash flow of +277.9bn.

Cash Conversion

TTM Cash Conversion · 2025Q1 -> 2026Q1

CFO TTM 292.5bn +192.1bn
Cash Capex 14.7bn −87.2bn
FCF TTM +277.9bn +279.3bn

Investment Takeaway

The business is entering a broader improvement phase — not just stronger earnings but better operating quality as well. Margin, ROIC, and cash flow all improving shows the business is growing in a cleaner and more efficient way than before. Notably, the improvement trend has been confirmed across multiple cycles, from margin to capital efficiency and cash generation. The residual risk still sits in working capital is tied up too long in the operating cycle, with CCC extended to 207 days.

Improvement: earnings conversion looks more confirmed, with CFO / net income at 0.82x.

Key risk: working capital remains tied up for too long, with cash cycle at 207.1 days.

Statement Data

Item 2025 2024 2023 2022 2021
Net Revenue
2,441.1 2,205.1 1,994.0 1,643.7 1,266.6
Cost of Goods Sold
1,439.5 1,349.6 1,183.5 946.4 0.0
Gross Profit
1,001.6 855.6 810.5 697.4 488.0
Financial Expenses
40.1 25.2 31.5 29.4 -18.0
Selling Expenses
378.3 312.1 309.9 269.0 -181.3
General and Administrative Expenses
160.8 128.3 119.6 131.8 -72.6
Operating Profit
445.0 403.3 374.4 290.6 234.5
Profit Before Tax
446.2 404.2 377.3 291.4 238.9
Net Income
349.1 320.9 299.6 223.5 189.1
Profit Attributable to Parent
349.1 320.9 299.6 223.5 189.1
Earnings per Share
1,976.00 1,932.00 3,637.00 2,951.00 2,600.00

Explore Other Stocks In The Same Sector

DHG, DVN, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, PMC, VDP, DHT, FIT, DHD, AGP, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DBT, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP

Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.